Basic Information
Cufence
Regulatory Information
EMEA/H/C/004111
Authorised
July 25, 2019
May 29, 2019
7
June 3, 2024
Company Information
Netherlands
Schouwburgplein 30-34 3012 CL Rotterdam
UNIVAR SOLUTIONS
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.
Overview Summary
Cufence is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage. Cufence is used in patients who cannot take D-penicillamine, another medicine for this condition. Cufence contains the active substance trientine dihydrochloride.